Skip to main content

Research Repository

Advanced Search

All Outputs (77)

Clinical relevance of biomarkers in oestrogen receptor positive breast cancer (2020)
Book Chapter
Parks, R. M., & Cheung, K. L. (2020). Clinical relevance of biomarkers in oestrogen receptor positive breast cancer. In G. G. Chen, M. C. Tong, & C. van Hasselt (Eds.), Estrogen receptors: structure, functions and clinical aspects (53-91). Nova Science Publishers

© 2020 Nova Science Publishers, Inc. Some biomarkers have been examined extensively in the context of breast cancer, including the oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). They are now routinely measured and used c... Read More about Clinical relevance of biomarkers in oestrogen receptor positive breast cancer.

Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome (2020)
Journal Article
Parks, R. M., Albanghali, M., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2020). Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome. Cancers, 12(8), Article 2067. https://doi.org/10.3390/cancers12082067

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The majority of biological profiling studies use surgical excision (SE) samples, excluding patients receiving nonsurgical and neoadjuvant therapy. We propose using core needle biopsy (CNB) for... Read More about Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome.

Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group (2020)
Journal Article
Battisti, N. M. L., Mislang, A. R., Cooper, L., O'Donovan, A., Audisio, R. A., Cheung, K. L., …Wildiers, H. (2020). Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. Journal of Geriatric Oncology, 11(8), 1190-1198. https://doi.org/10.1016/j.jgo.2020.07.008

© 2020 Elsevier Inc. The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the... Read More about Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.

Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study (2020)
Journal Article
Morgan, J. L., George, J., Holmes, G., Martin, C., Reed, M. W. R., Ward, S., …Bridging the Age Gap Trial Management Team. (2020). Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study. British Journal of Surgery, https://doi.org/10.1002/bjs.11617

© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd on behalf of BJS Society Ltd Background: Breast cancer surgery in older women is variable and sometimes non-standard owing to concerns about morbidity. Bridging the A... Read More about Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study.

Correlation between breast cancer and lifestyle within the Gulf Cooperation Council countries: A systematic review (2020)
Journal Article
Tanner, L. T. A., & Cheung, K. L. (2020). Correlation between breast cancer and lifestyle within the Gulf Cooperation Council countries: A systematic review. World Journal of Clinical Oncology, 11(4), 217-242. https://doi.org/10.5306/wjco.v11.i4.217

BACKGROUND
In the six Gulf Cooperation Council countries (GCCCs), Bahrain, Saudi Arabia, Kuwait, Oman, Qatar and the United Arab Emirates, breast cancer (BC) is the greatest cause of cancer incidence and mortality. Obesity and physical inactivity ar... Read More about Correlation between breast cancer and lifestyle within the Gulf Cooperation Council countries: A systematic review.

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer (2020)
Journal Article
Robertson, J. F., Evans, A., Henschen, S., Kirwan, C. C., Jahan, A., Kenny, L. M., …Harbeck, N. (2020). A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer. Clinical Cancer Research, 26(16), 4242-4249. https://doi.org/10.1158/1078-0432.CCR-19-3387

©2020 American Association for Cancer Research. PURPOSE: Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limit... Read More about A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.

Treatment strategies and survival outcomes in breast cancer (2020)
Journal Article
Cheung, K. L. (2020). Treatment strategies and survival outcomes in breast cancer. Cancers, 12(3), Article 735. https://doi.org/10.3390/cancers12030735

Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and system... Read More about Treatment strategies and survival outcomes in breast cancer.

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy (2019)
Journal Article
Luveta, J., Parks, R. M., Heery, D. M., Cheung, K.-L., & Johnston, S. J. (2020). Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. Oncology and Therapy, 8, 1-11. https://doi.org/10.1007/s40487-019-00105-0

Invasive lobular carcinoma comprises 10–15% of all breast cancers and is increasingly recognised as a distinct and understudied disease compared with the predominant histological subtype, invasive ductal carcinoma. Hallmarks of invasive lobular carci... Read More about Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.

Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT) (2019)
Journal Article
Robertson, J. F., Coleman, R. E., Cheung, K.-L., Evans, A., Holcombe, C., Skene, A., …Gee, J. M. (2020). Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26(7), 1574-1585. https://doi.org/10.1158/1078-0432.CCR-19-3053

© 2020 American Association for Cancer Research Inc.. All rights reserved. Purpose: The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therape... Read More about Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT).

Personalising Care in the Older Woman with Primary Breast Cancer (2019)
Journal Article
Parks, R. M., & Cheung, K. L. (2019). Personalising Care in the Older Woman with Primary Breast Cancer. Annals of the Academy of Medicine, Singapore, 48(11), 370-375

The incidence of breast cancer increases with age. Despite this, most research in the field is targeted at younger patients. Age-specific guidelines are not widely referred to and guidelines which allude to the older woman as an individual are based... Read More about Personalising Care in the Older Woman with Primary Breast Cancer.

Early-Stage Breast Cancer in Older Adults (2019)
Book Chapter
Cheung, K.-L., Livi, L., & Brain, E. (2019). Early-Stage Breast Cancer in Older Adults. In M. Extermann (Ed.), Geriatric Oncology (1-10). Cham, Switzerland: Springer. https://doi.org/10.1007/978-3-319-44870-1_33-1

Breast cancer is the most common cancer afflicting women worldwide. Its incidence peaks around 70, while mortality increases greatly after 75 years old. Given the competing risks on mortality with multimorbidities, geriatric assessment is a leitmotiv... Read More about Early-Stage Breast Cancer in Older Adults.

Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women (2019)
Journal Article
Syed, B. M., Green, A. R., Morgan, D. A., Ellis, I. O., & Cheung, K. (2019). Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women. Cancers, 11(2), 1-17. https://doi.org/10.3390/cancers11020149

Background: The role of liver kinase B1 (LKB1), a serine/threonine kinase, has been described in the development of PeutzJagher’s syndrome, where a proportion (~45%) of patients have developed breast cancer in their lifetime. Cell line studies have l... Read More about Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women.

Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition (2018)
Journal Article
Chen, X., Low, K. H., Alexander, A., Jiang, Y., Karakas, C., Hess, K. R., …Keyomarsi, K. (2018). Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.ccr-18-1446

Purpose: Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and phosphorylated-CDK2 are correlated with poor survival in TNBC patients,... Read More about Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.

Endocrine therapy for breast cancer: a model of hormonal manipulation (2018)
Journal Article
Johnston, S. J., & Cheung, K.-L. (in press). Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncology and Therapy, https://doi.org/10.1007/s40487-018-0062-x

Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited... Read More about Endocrine therapy for breast cancer: a model of hormonal manipulation.

Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort (2018)
Journal Article
Schuil, H., Derks, M., Liefers, G.-J., Portielje, J., van de Velde, C., Syed, B., Green, A., Ellis, I., Cheung, K.-L., & Bastiaannet, E. (in press). Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort. Journal of Geriatric Oncology, https://doi.org/10.1016/j.jgo.2018.05.004

Objective: Clinical trials investigating breast cancer treatment often exclude or misrepresent older adults. This study compares treatment patterns and survival of older women diagnosed with breast cancer between a Dutch and a British observational c... Read More about Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort.

Fulvestrant for the treatment of advanced breast cancer (2018)
Journal Article
Blackburn, S. A., Parks, R. M., & Cheung, K.-L. (2018). Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 18(7), 619-628. https://doi.org/10.1080/14737140.2018.1473038

Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degr... Read More about Fulvestrant for the treatment of advanced breast cancer.

Optimising endocrine therapy in postmenopausal women with advanced breast cancer (2018)
Journal Article
Yau, T. H. L., & Cheung, K.-L. (2018). Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocrine-Related Cancer, 25(7), 705-721. https://doi.org/10.1530/ERC-18-0021

Hormone receptor-positive breast cancer is commonly treated with endocrine therapy; however, overtime cancer cells can develop endocrine resistance. This review aims to document combination therapy and sequential therapy in the use of endocrine agent... Read More about Optimising endocrine therapy in postmenopausal women with advanced breast cancer.